TL;DR — SIRT1 needs NAD+ (NMN) and an activator (resveratrol) — neither alone is complete. AM fasted NMN + PM fat-paired resveratrol mimics circadian NAD+A molecule every cell needs for energy production, DNA repair, and activating longevity genes (sirtuins). Full glossary → rhythm. Run 12–24 weeks; NAD+ index at week 4 is the primary checkpoint.
Why this stack exists
SIRT1 deacetylates histones, PGC-1α, and metabolic regulators — but it is strictly NAD+-dependent. Resveratrol allosterically boosts SIRT1 activity yet cannot overcome empty NAD+ pools. NMN restores NAD+ but does not directly activate SIRT1.
| Layer | Compound | Role | Analogy |
|---|---|---|---|
| Cofactor | NMN | Restores NAD+ pools | Key |
| Activator | Resveratrol | Allosteric SIRT1 boost | Turn |
← Swipe for more columns →
Gap analysis — what breaks when you use only one:
- NMN alone → NAD+ rises; SIRT1/PGC-1α signaling may stay flat without activator
- Resveratrol alone → SIRT1 stimulated but starved of cosubstrate — "revving without fuel"
- Combined → cofactor + activator completes the deacetylation cycle
Suggested visual
Suggested visual: Lock-and-key diagram — NAD+ (key from NMN) + resveratrol (activator) → SIRT1 → deacetylation targets (PGC-1α, p53, NF-κB). Split AM/PM timeline below.
Mechanistic synergyWhen two compounds together produce greater effect than either alone. Full glossary → map
`
AM (fasted): [NMN] → NAD+ pool ↑ → SIRT3 mitophagyA specific form of autophagy that selectively removes damaged or dysfunctional mitochondria, replacing them with healthy ones. Full glossary → + PARP substrate
↓
PM (with fat): [Resveratrol] → SIRT1 allosteric activation
↓
Output: PGC-1α → mitochondrial biogenesis
Histone deacetylation → epigenetic stability
NF-κB modulation → ↓ inflammagingChronic low-grade inflammation that increases with age and damages tissues silently. Full glossary →
`
Hallmarks addressed: Mitochondrial dysfunction · Epigenetic alterations · Disabled autophagyThe cellular self-cleaning process that breaks down and recycles damaged proteins, organelles, and pathogens. Full glossary → · Disabled macroautophagy · Chronic inflammation — with mechanistic complementarity (not redundancy).
Evidence per leg
| Compound | Tier | Key human data |
|---|---|---|
| NMN | A | NAD+ elevation, functional signals (PMID 36482258) |
| Resveratrol | B | Strong SIRT1/AMPK mechanism; mixed standalone human outcomes |
| Combination | B | Mechanistic synergy established; limited combination RCTs |
Combination logic: No completed RCT tested NMN + resveratrol as a fixed pair. Architecture grades Tier B — same standard as mechanistic stack reviews when legs are strong but combination data is preclinical/review-level.
Igarashi 2022 (PMID 36482258): NMN raises NAD+ in humans. PMID 30930169: NAD+ precursors and sirtuin activators synergize for mitochondrial health. Pair graded Tier B pending combination RCT.
Is the SIRT1 pair right for you?
Sleep 7+ hrs and Zone 2 ≥150 min/wk for 4+ weeks?
node | NAD+ below 80 OR morning energy ≤5/10?
node | On blood thinners or diabetes medications?
redflag | Physician clearance — resveratrol CYP/platelet and AMPK glucose effects
Start NMN 250 mg AM week 1–4 → add resveratrol 150 mg PM week 5
Run NMN-only 12-week trial first → add resveratrol if plateau
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
AM/PM choreography (non-negotiable spacing)
| Step | Time | Compound | Dose | Notes |
|---|---|---|---|---|
| 1 | AM fasted (wake + 30 min) | NMN | 250 mg → 500 mg | Titrate over 4 weeks |
| 2 | PM dinner (with fat) | Trans-resveratrol | 150 mg → 250–500 mg | ≥15 g dietary fat |
| 3 | Optional week 8+ | Ca-AKG | 1 g AM | Upgrade to NAD+ Mito Stack |
← Swipe for more columns →
Why spacing matters: NMN absorption is optimized fasted AM; resveratrol needs fat co-ingestion PM. Split timing mimics natural circadian NAD+ rhythm (daytime peak) and avoids competing absorption windows.
Day-one setup (15 minutes)
- Label AM and PM bottles physically separate
- Set wake alarm + dinner alarm for dose pairing
- Baseline NAD+ index (or schedule week-4 draw)
- Log AM energy and sleep quality daily in journal
- Read NMN and Resveratrol deep dives
Biomarker targets
| Marker | Baseline | 12 wk | 24 wk | Stack success signal |
|---|---|---|---|---|
| NAD+ index | Log | 80–100 | 80–100 | Primary |
| Morning energy (1–10) | Log | ≥7 | ≥7 | Primary |
| HbA1c | Log | <5.7% | <5.7% | Secondary (AMPKAn energy-sensing enzyme activated when ATP is low — it promotes fat burning, mitochondrial biogenesis, and autophagy. Full glossary →) |
| Resting HR | Wearable | ↓ 2–5 bpm | Stable low | Mito proxy |
← Swipe for more columns →
NAD+ index
60–75
Morning energy (1–10)
≤5
HbA1c (%)
5.5–5.9
NAD+ index
80–100
Morning energy (1–10)
≥7
HbA1c (%)
<5.7
Track stack biomarkers
Minimum panel: NAD+ index at week 4 and 12; HbA1c at 6 months if metabolic hallmark active.
Open Labs hubRed flags and contraindications
Hard stops — do not run this stack without clearance
- Warfarin, antiplatelet agents, or bleeding disorder — resveratrol theoretical platelet effects
- Insulin or sulfonylurea therapy — AMPK activation risks hypoglycemia
- Pregnancy or breastfeeding — insufficient safety data for high-dose NAD+ precursors
Soft cautions
Resveratrol GI upset — take with largest fat-containing meal. NMN afternoon dosing may disrupt sleep in sensitive individuals — keep AM only. Do not combine high-dose NMN + NR without physician oversight.
Stack variants by budget
| Tier | Components | Monthly est. | Coverage |
|---|---|---|---|
| Starter | NMN 250 mg AM only | $ | NAD+ fuel; missing activator |
| Core pair | NMN AM + resveratrol PM | $$ | Full SIRT1 cycle |
| Full mito | + Ca-AKG + R-ALA | $$$ | NAD+ Mito Stack coverage |
← Swipe for more columns →
When to upgrade to NAD+ Mito Stack
Add Ca-AKG at week 8–12 if: (1) NAD+ responded but energy plateaued, (2) epigenetic hallmark is co-primary, (3) training load is high and TCA flux support is needed. Do not start all four compounds day one.
Personal results template
My SIRT1 pair log
| Date | Week | NMN AM ✓ | Resv PM ✓ | NAD+ index | Energy | Sleep | Notes |
|---|---|---|---|---|---|---|---|
| YYYY-MM-DD | 0 | — | — | — | — | — | Baseline |
| YYYY-MM-DD | 4 | ✓ | — | — | — | — | NMN ramp |
| YYYY-MM-DD | 12 | ✓ | ✓ | — | — | — | Primary endpoint |
| YYYY-MM-DD | 24 | ✓ | ✓ | — | — | — | Full trial |
← Swipe for more columns →
Compliance target: ≥85% daily adherence on both legs
Response criteria: - Win: NAD+ ≥80 + energy ≥7/10 at week 12 - Iterate: NAD+ OK but energy flat → upgrade to NAD+ Mito Stack or audit sleep/training - Stop signal: Bruising, hypoglycemia, or insomnia → discontinue resveratrol, physician consult
Enable SIRT1 pair
Pre-built SIRT1 pair with AM/PM synergy scoring — enable NMN leg before resveratrol for architect validation.
Open Stack ArchitectReferences
- Fukamizu Y et al. NMN supplementation elevates NAD+ levels in healthy adults. GeroScience (2022). PMID 36482258
- PMID 30930169
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.